Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
Humans
Macrophage Activation Syndrome
/ etiology
Male
Female
Child
Arthritis, Juvenile
/ complications
Child, Preschool
Adolescent
Ferritins
/ blood
Lupus Erythematosus, Systemic
/ complications
Blood Sedimentation
Retrospective Studies
Platelet Count
Mucocutaneous Lymph Node Syndrome
/ complications
Ferritin
Interleukin (IL)-18
Kawasaki disease
Macrophage activation syndrome
Rheumatic diseases
Systemic juvenile idiopathic arthritis
Systemic lupus erythematosus
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
05
11
2023
accepted:
25
04
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
Macrophage activation syndrome (MAS), an example of secondary hemophagocytic lymphohistiocytosis, is a potentially fatal complication of rheumatic diseases. We aimed to study the clinical and laboratory characteristics, treatment schemes, and outcomes of different rheumatic disorders associated with MAS in children. Early warning indicators of MAS have also been investigated to enable clinicians to make a prompt and accurate diagnosis. Fifty-five patients with rheumatic diseases complicated by MAS were enrolled between January 2017 and December 2022. Clinical and laboratory data were collected before disease onset, at diagnosis, and after treatment with MAS, and data were compared between patients with systemic juvenile idiopathic arthritis (sJIA), Kawasaki disease (KD), and systemic lupus erythematosus (SLE). A random forest model was established to show the importance score of each variable with a significant difference. Most (81.8%) instances of MAS occurred during the initial diagnosis of the underlying disease. Compared to the active stage of sJIA, the platelet count, erythrocyte sedimentation rate, and fibrinogen level in sJIA-MAS were significantly decreased, whereas ferritin, ferritin/erythrocyte sedimentation rate, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and D-dimer levels were significantly increased. Ferritin level, ferritin/erythrocyte sedimentation rate, and platelet count had the greatest predictive value for sJIA-MAS. The level of IL-18 in the sJIA-MAS group was significantly higher than in the active sJIA group, whereas IL-6 levels were significantly lower. Most patients with MAS were treated with methylprednisolone pulse combined with cyclosporine, and no deaths occurred. Thrombocytopenia, ferritin levels, the ferritin/erythrocyte sedimentation rate, and elevated aspartate aminotransferase levels can predict the occurrence of MAS in patients with sJIA. Additionally, our analysis indicates that IL-18 plays an important role in the pathogenesis of MAS in sJIA-MAS.
Sections du résumé
BACKGROUND
BACKGROUND
Macrophage activation syndrome (MAS), an example of secondary hemophagocytic lymphohistiocytosis, is a potentially fatal complication of rheumatic diseases. We aimed to study the clinical and laboratory characteristics, treatment schemes, and outcomes of different rheumatic disorders associated with MAS in children. Early warning indicators of MAS have also been investigated to enable clinicians to make a prompt and accurate diagnosis.
METHODS
METHODS
Fifty-five patients with rheumatic diseases complicated by MAS were enrolled between January 2017 and December 2022. Clinical and laboratory data were collected before disease onset, at diagnosis, and after treatment with MAS, and data were compared between patients with systemic juvenile idiopathic arthritis (sJIA), Kawasaki disease (KD), and systemic lupus erythematosus (SLE). A random forest model was established to show the importance score of each variable with a significant difference.
RESULTS
RESULTS
Most (81.8%) instances of MAS occurred during the initial diagnosis of the underlying disease. Compared to the active stage of sJIA, the platelet count, erythrocyte sedimentation rate, and fibrinogen level in sJIA-MAS were significantly decreased, whereas ferritin, ferritin/erythrocyte sedimentation rate, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and D-dimer levels were significantly increased. Ferritin level, ferritin/erythrocyte sedimentation rate, and platelet count had the greatest predictive value for sJIA-MAS. The level of IL-18 in the sJIA-MAS group was significantly higher than in the active sJIA group, whereas IL-6 levels were significantly lower. Most patients with MAS were treated with methylprednisolone pulse combined with cyclosporine, and no deaths occurred.
CONCLUSIONS
CONCLUSIONS
Thrombocytopenia, ferritin levels, the ferritin/erythrocyte sedimentation rate, and elevated aspartate aminotransferase levels can predict the occurrence of MAS in patients with sJIA. Additionally, our analysis indicates that IL-18 plays an important role in the pathogenesis of MAS in sJIA-MAS.
Identifiants
pubmed: 38783316
doi: 10.1186/s12969-024-00991-3
pii: 10.1186/s12969-024-00991-3
doi:
Substances chimiques
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Subventions
Organisme : National Natural Science Foundation of China
ID : 81202345
Organisme : National Natural Science Foundation of China
ID : 81771762, and 82271838
Informations de copyright
© 2024. The Author(s).
Références
Ravelli A, Davì S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29:927–41. https://doi.org/10.1016/j.hoc.2015.06.010 .
doi: 10.1016/j.hoc.2015.06.010
pubmed: 26461152
Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289–98. https://doi.org/10.1038/gene.2012.3 .
doi: 10.1038/gene.2012.3
pubmed: 22418018
Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015;11:1043–53. https://doi.org/10.1586/1744666X.2015.1058159 .
doi: 10.1586/1744666X.2015.1058159
pubmed: 26082353
Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8. PMID:17343315.
pubmed: 17343315
Zeng HS, Xiong XY, Wei YD, Wang HW, Luo XP. Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis. World J Pediatr. 2008;4:97–101. https://doi.org/10.1007/s12519-008-0018-6 .
doi: 10.1007/s12519-008-0018-6
pubmed: 18661762
pmcid: 7102092
Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:3160–9. https://doi.org/10.1002/art.38802 .
doi: 10.1002/art.38802
pubmed: 25077692
Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2:e000161. https://doi.org/10.1136/rmdopen-2015-000161 .
doi: 10.1136/rmdopen-2015-000161
pubmed: 26848401
pmcid: 4731834
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. https://doi.org/10.3389/fimmu.2019.00119 .
doi: 10.3389/fimmu.2019.00119
pubmed: 30774631
pmcid: 6367262
Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66:3486–95. https://doi.org/10.1002/art.38793 .
doi: 10.1002/art.38793
pubmed: 25047945
pmcid: 4321811
Vastert SJ, van Wijk R, D’Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatol (Oxf Engl). 2010;49:441–9. https://doi.org/10.1093/rheumatology/kep418 .
doi: 10.1093/rheumatology/kep418
Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892–6. https://doi.org/10.1002/art.23734 .
doi: 10.1002/art.23734
pubmed: 18759271
pmcid: 2779064
Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6:137–54. https://doi.org/10.1586/eci.09.58 .
doi: 10.1586/eci.09.58
pubmed: 20383897
Tripathy R, Panda AK, Das BK. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE. Lupus. 2015;24(1):82–9. https://doi.org/10.1177/0961203314552290 .
doi: 10.1177/0961203314552290
pubmed: 25253568
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton, 2001. J Rheumatol. 2004;31(2):390–2. PMID: 14760812.
pubmed: 14760812
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747–71. https://doi.org/10.1161/01.CIR.0000145143.19711.78 .
doi: 10.1161/01.CIR.0000145143.19711.78
pubmed: 15505111
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic Lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86. https://doi.org/10.1002/art.34473 .
doi: 10.1002/art.34473
pubmed: 22553077
pmcid: 3409311
Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68:566–76. https://doi.org/10.1002/art.39332 .
doi: 10.1002/art.39332
pubmed: 26314788
Parodi A, Davì S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60:3388–99. https://doi.org/10.1002/art.24883 .
doi: 10.1002/art.24883
pubmed: 19877067
Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71:1943–54. https://doi.org/10.1002/art.41073 .
doi: 10.1002/art.41073
pubmed: 31379071
pmcid: 6817389
Guo L, Xu Y, Qian X, et al. Sudden hypotension and increased serum Interferon-γ and Interleukin-10 predict early macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Pediatr. 2021;235:203–e2113. https://doi.org/10.1016/j.jpeds.2021.02.008 .
doi: 10.1016/j.jpeds.2021.02.008
pubmed: 33581106
Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117–28. https://doi.org/10.2147/OARRR.S151013 .
doi: 10.2147/OARRR.S151013
pubmed: 30214327
pmcid: 6124446
Han SB, Lee SY. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches. World J Pediatr. 2020;16:566–74. https://doi.org/10.1007/s12519-020-00360-6 .
doi: 10.1007/s12519-020-00360-6
pubmed: 32418074
Naveen R, Jain A, Muhammed H, et al. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities. Rheumatol Int. 2021;41(3):625–31. https://doi.org/10.1007/s00296-020-04763-6 .
doi: 10.1007/s00296-020-04763-6
pubmed: 33388903
Eloseily EMA, Minoia F, Crayne CB, Beukelman T, Ravelli A, Cron RQ. Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2019;1(6):345–9. https://doi.org/10.1002/acr2.11048 .
doi: 10.1002/acr2.11048
pubmed: 31777812
pmcid: 6857981
Sen ES, Clarke SL, Ramanan AV. Macrophage activation syndrome. Indian J Pediatr. 2016;83:248–53. https://doi.org/10.1007/s12098-015-1877-1 .
doi: 10.1007/s12098-015-1877-1
pubmed: 26400031
Mizuta M, Shimizu M, Irabu H, Usami M, Inoue N, Nakagishi Y, et al. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatol (Oxf Engl). 2021;60:231–8. https://doi.org/10.1093/rheumatology/keaa299 .
doi: 10.1093/rheumatology/keaa299
Weiss ES, Girard-Guyonvarc’h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442–55. https://doi.org/10.1182/blood-2017-12-820852 .
doi: 10.1182/blood-2017-12-820852
pubmed: 29326099
pmcid: 5877443
McClain KL, Allen CE. Fire behind the fury: il-18 and MAS. Blood. 2018;131:1393–4. https://doi.org/10.1182/blood-2018-02-828186 .
doi: 10.1182/blood-2018-02-828186
pubmed: 29599143
Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc’H C, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatol (Oxf Engl). 2020;59:361–6. https://doi.org/10.1093/rheumatology/kez282 .
doi: 10.1093/rheumatology/kez282
Lin CI, Yu HH, Lee JH, Wang LC, Lin YT, Yang YH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012;31:1223–30. https://doi.org/10.1007/s10067-012-1998-0 .
doi: 10.1007/s10067-012-1998-0
pubmed: 22615046
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatol (Oxf Engl). 2011;50:417–9. https://doi.org/10.1093/rheumatology/keq218 .
doi: 10.1093/rheumatology/keq218
Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97–107. https://doi.org/10.1038/nrrheum.2013.157 .
doi: 10.1038/nrrheum.2013.157
pubmed: 24166241
Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326–34. https://doi.org/10.1002/art.41103 .
doi: 10.1002/art.41103
pubmed: 31513353
Wu J, Sun L, Tang X, Zheng Q, Guo L, Xu L, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome. Mod Rheumatol. 2022;32:1114–21. https://doi.org/10.1093/mr/roab119 .
doi: 10.1093/mr/roab119
pubmed: 34971386
De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82:857–65. https://doi.org/10.1136/ard-2022-223739 .
doi: 10.1136/ard-2022-223739
pubmed: 37001971
Junga Z, Stitt R, Tracy C, Keith M. Novel use of Rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus. BMJ Case Rep. 2017;2017:bcr2017221347. https://doi.org/10.1136/bcr-2017-221347 .
doi: 10.1136/bcr-2017-221347
pubmed: 28827301
pmcid: 5624074